Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from thePharmaLetter

20:12 EDT 20th August 2018 | BioPortfolio

Here are the most relevant search results for "thePharmaLetter" found in our extensive news archives from over 250 global news sources.

More Information about thePharmaLetter on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about thePharmaLetter for you to read. Along with our medical data and news we also list thePharmaLetter Clinical Trials, which are updated daily. BioPortfolio also has a large database of thePharmaLetter Companies for you to search.

Showing News Articles 1–25 of 1,500+ from thePharmaLetter

Thursday 17th May 2018

Cuba to access rituximab biosimilar through Biocad

Russian biosimilar manufacturer Biocad has had its rituximab equivalent approved by the Cuban Ministry…

AstraZeneca continues legal battles in Russia

For the second time, Anglo-Swedish pharma major AstraZeneca is trying to stop the marketing of a generic…

Crysvita meets goal in Phase III study for X-Linked hypophosphatemia

US ultra-rare diseases focussed biotech firm Ultragenyx Pharmaceutical and Japan’s Kyowa Hakko Kirin…

Two-year-old firm attracts quarter-billion dollar investment in China

A record-breaking $260 million has been raised by CStone Pharmaceuticals, the largest series B financing…

BRIEF—Celyad announces pricing of $47.3 million global offering

Belgium’s Celyad today announced the pricing of a global offering of 1,800,000 ordinary shares.

USA reports ongoing IP challenges as China extends drug exclusivity period

For the 14th consecutive year, the USTR has put China on a ‘priority watch list' on its annual analysis…

BRIEF—Tecentriq secures positive UK reimbursement decision

Roche has won reimbursement in the UK for its immunotherapy Tecentriq (atezolizumab) as a second-line…

Astellas rejects overcharging claims

Astellas has defended its practices following the publication of a report suggesting that its prostate…

BRIEF—$20.5 million for EIP Pharma to develop Alzheimer's candidate

CNS disease specialist EIP Pharma has raised $20.5 million in a series B financing round led by Access…

Why sponsors need a global view of clinical trial compliance

Francine Lane, vice president of global transparency at TrialScope, writes an Expert View on the challenges…

March of approvals for cabozantinib continues with first-line kidney cancer nod

French pharma firm Ipsen is trading about 2% higher in Paris today, on news that Cabometyx (cabozantinib),…

First non-opioid-based therapy for opioid withdrawal symptoms wins US backing

Specialty pharma firm US WorldMeds has been approved to market Lucemyra (lofexidine), the firm’s opioid…

End Brexit uncertainty for at-risk UK pharma sector, says cross-party committee

A report concludes that the prospect of leaving the European Union (EU) without an agreement that protects…

R-Pharm and AbbVie to start supplying new hepatitis C drug for state needs in Russia

R-Pharm, one of Russia’s leading drugmakers, has won a tender in Russia for the supply of Viekira Pak…

Repatha gains expanded indication in Europe

The European Commission (EC) has approved a new indication in the Repatha (evolocumab) label for adults…

Lilly diabetes exec joins AmideBio as CEO

AmideBio, a privately held US biotech company, has announced that Dr Pawel Fludzinski has joined the…

BRIEF—Eleven Biotherapeutics changes name to Sesen Bio

USA-based oncology specialist Eleven Biotherapeutics has announced that the company is changing its name…

Merck KGaA's Healthcare CEO looking 'beyond treatment' to combat diabetes

Belén Garijo has been the chief executive of the Healthcare business of German life sciences group Merck…

Wednesday 16th May 2018

Panacea has new CEO to add to new name

Sensei Biotherapeutics, a privately-held company known as Panacea Pharmaceuticals until earlier this…

Roche terminates agreement with NewLink

Genentech, the biotech unit of Swiss pharma giant Roche, has brought an end to its license and collaboration…

Third time lucky for Pfizer’s third biosimilar

US pharma giant Pfizer has advanced its number of approved biosimilar medicines in the USA to three.

BRIEF — Promethera estalishes Tokyo branch

Belgian bioscience firm Promethera has announced the foundation of a new Tokyo office, Promethera Biosciences…

Celsius launches with $65 million and licenses from Broad Institute

A single-cell genomic sequencing company has been launched following a $65 million Series A financing…

Newly-formed company in-licenses LEO Pharma antibiotics

Denmark's LEO Pharma has done a deal to give UTILITY therapeutics an exclusive license for the antibiotics…

Eiger expanding deal with Merck for lonafarnib

Eiger BioPharmaceuticals has expanded its licensing agreement with Merck & Co to include rights to develop…


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks